Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3037526 | 0.71 | KMT2A (0.45) | KMT2AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL3035305 | 0.71 | KMT2A (0.45) | KMT2AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL28999586 | 0.65 | — | — | |
| SCHEMBL30073129 | 0.65 | LMNA (0.40) | KMT2AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL12534280 | 0.64 | — | — | |
| SCHEMBL2958326 | 0.63 | KMT2A (0.46) | KMT2AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL4337709 | 0.62 | KMT2A (0.41) | KMT2AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL749892 | 0.62 | PIK3CD (0.58) | KMT2AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL1729874 | 0.62 | KMT2A (0.41) | KMT2AMAPTMEN1CYP3A4CYP2C9 | |
| SCHEMBL268537 | 0.62 | KMT2A (1.00) | KMT2AMAPTKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100202989-A1 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | WANG BING | 2010-08-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100202989-A1 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | KRT18, CUTA, TUBB1 | KMT2A 3319/4885MAPT 1044/4885KDM4E 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.